您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Dexrazoxane(NSC-169780)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Dexrazoxane(NSC-169780)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Dexrazoxane(NSC-169780)图片
CAS NO:24584-09-6
规格:≥98%
包装与价格:
包装价格(元)
50mg电议
100mg电议
250mg电议
500mg电议
1g电议
5g电议
10g电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)268.27
FormulaC11H16N4O4
CAS No.24584-09-6 (free base)
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: N/A
Water: N/A
Ethanol: <1 mg/mL
Other infoChemical Name: (S)-4,4'-(propane-1,2-diyl)bis(piperazine-2,6-dione)
SMILES Code: C[C@H](N(C1)CC(NC1=O)=O)CN(C2)CC(NC2=O)=O
SynonymsICRF-187 (ADR-529) HCl; (+)-Razoxane hydrochloride, ADR-529 hydrochloride, Cardioxan, Dexrazoxane HCl, Dexrazoxane hydrochloride, ICRF-187 hydrochloride, Savene; ADR529; ADR-529; ADR 529; ICRF-187; ICRF187; ICRF 187; NSC169780; NSC-169780; NSC 169780; Cardioxan; Cardioxane; US brand names: Totect; Zinecard. Foreign brand names: Cardioxane Savene.
实验参考方法
In Vitro

In vitro activity: Dexrazoxane (10 mM), known clinically to limit anthracycline cardiac toxicity, prevents daunorubicin-induced myocyte apoptosis, but not necrosis induced by higher anthracycline concentrations in rat cardiac myocytes. Dexrazoxane presumably exerts its cardioprotective effects by either binding free or loosely bound iron, or iron complexed to doxorubicin, thus preventing or reducing site-specific oxygen radical production that damages cellular components. Dexrazoxane specifically abolishes the DNA damage signal gamma-H2AX induced by doxorubicin, but not camptothecin or hydrogen peroxide, in H9C2 cardiomyocytes. Dexrazoxane also induces rapid degradation of Top2beta, which paralleles the reduction of doxorubicin-induced DNA damage. Dexrazoxane antagonizes doxorubicin-induced DNA damage through its interference with Top2beta, which could implicate Top2beta in doxorubicin cardiotoxicity. Dexrazoxane is hydrolyzed to its active form intracellularly and binds iron to prevent the formation of superhydroxide radicals, thus preventing mitochondrial destruction.

In VivoDexrazoxane combined with doxorubicin, daunorubicin, or idarubicin reduces the tissue lesions in B6D2F1 mice (expressed as area under the curve of wound size times duration) by 96%, 70%, and 87%, respectively. Dexrazoxane combined with doxorubicin, daunorubicin, or idarubicin results in a statistically significant reduction in the fraction of mice with wounds as well as the duration of wounds.
Animal modelB6D2F1 mice
Formulation & DosageN/A
ReferencesCirc Res. 1999 Feb 19;84(3):257-65; Cancer Res. 2007 Sep 15;67(18):8839-46; Clin Cancer Res. 2000 Sep;6(9):3680-6.